Merck is a large drug maker. Keytruda helps the immune system attack cancer and is approved for over 45 uses in America; hospitals buy it, paid by insurers and Medicare.
Bristol's Opdivo is the older rival, and copies are already in trials.
Is it a good business? · 6 · What does its record show?
Sales rose, growth has slowed
Sales, $B
48.7
59.3
60.1
64.2
65.0
67.4
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$48.7B → $67.4Bsales, 2021 to the past year
Growth+1.3%sales growth in 2025
Cash$8.67B → $14.7Bfree cash
Making and selling got cheaper per dollar; research costs swing with the deals charged to it.
Is it a good business? · 7 · How much room is there to grow?
Half of US cancer patients could qualify
About 2.1 millionAmericans diagnosed with cancer, 2026
About $8,900of US Keytruda sales per new case
20 millionnew cases a year elsewhere
Nobody has measured eligibility since 2018, and the rest of the world pays far less.
Is it a good business? · 8 · Who is in charge?
A former finance chief runs it
2021Robert Davis became chief executive
2014when he joined as finance chief
2025sales missed the board's target
The shares lagged rival drug makers over three years.
The story right now · 9 · What happens when a patent ends?
Copies arrive and prices collapse
2028Keytruda's main patent ends
49%of Merck's 2025 sales came from Keytruda
Early 2027Medicare may set its price
When a drug's patent ends, cheaper copies can be sold and its sales usually fall steeply. Drug makers race to replace that income before the date arrives.
The story right now · 10 · How can Merck soften the cliff?
A new patented version keeps patients
Keytruda's patent ends2028.
Qlex, injected in minutesPatented to 2043.
Patients switch over$830M a quarter already.
Patent cases in courtUnresolved.
A patent holder has already stopped Qlex in part of Europe, and a German appeal is heard on 19 November.
The story right now · 11 · What changed lately?
Sales up 5%, the injected version climbing
$830MQlex sales, from $463M
$694MWinrevair sales, nearly doubled
About $550Mof growth from buying timing
$66.8B to $67.3Braised sales forecast
Solid quarter
Summit's head-to-head lung-cancer result is due by the end of 2026.
The story right now · 12 · What is everyone arguing about?
A shallow dip, or a hard cliff?
Many investors think
A shallow dip, carried by many new medicines
We think
Possible, but the injected version is in court
Against us: three late-stage trial wins this year and a cholesterol pill approved.
The price and our view · 13 · What is a share worth?
The price pays for a smooth passage past the patent
$115what we think a share is worth · the last close is of that
$115our value
Attractive below $91.83
Neutral
Unattractive above $138
$65.17gloomy: growth halves, less kept per $1
$115our estimate: experts' path, then slowing
$143sunny: growth beats the forecast by a quarter
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.
The price and our view · 14 · How could we be wrong?
Patent cases and copies
Qlex blocked in courtBiggest
Patent cases open.
Copies from 2028Watch
Amgen and others.
Medicare price-settingShowing now
Expected early 2027.
Replacement salesUnknown
Most not on sale.
Summit's rival drug could also beat Keytruda in lung cancer.
The price and our view · 15 · How will we know?
19 November starts the test run
German court rules for QlexGood sign
Summit's drug fails to beat KeytrudaGood sign
Medicare picks KeytrudaBad sign
FEB 202710
Fourth-quarter and full-year 2026 results, 10 February. Companies report every three months; each report is a test of the story.
Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.
The price and our view · 16 · So, what do we think?
Keytruda pays, but its patent clock runs out
$115our value
Attractive below $91.83
Neutral
Unattractive above $138
UnattractiveMedium conviction
Keytruda is very profitable, but half of sales rests on it, its patent ends in 2028 and sales barely grew for three years. The price sits above even our sunny future.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
Merck makes prescription medicines and vaccines, and one of them dominates. Keytruda is an antibody, given by drip in hospital, that blocks a protein cancer cells use to switch the immune system off. It is approved for over 45 uses in America, one cancer at a time since 2014.
Hospitals and cancer clinics buy it, paid by insurers and Medicare. Without it a patient would get chemotherapy, a rival drug such as Bristol's Opdivo, or, after surgery, simply wait to see whether the cancer returns.
How it makes money
Merck sells each dose to a few large wholesalers, who resell it to hospitals and pharmacies; insurers pay most of the bill after rebates. Keytruda brought in half of all sales in 2025.
The rest is spread out: vaccines such as Gardasil, which fell sharply when sales to China stopped, newer drugs such as Winrevair for blood pressure in the lungs, and medicines for pets and farm animals, about a tenth of sales.
Growth and profit
What growth costs
Making and selling each medicine costs less per dollar of sales than four years ago, so growing has made Merck more profitable. Research is the cost that jumps, because Merck charges the companies it buys to research in the year it buys them.
Its record
The numbers
Is it growing?Slow
Sales grew 4.9% over the twelve months to Sep 2026, about the same pace as the 1.3% in the year to Dec 2025.
Is it profitable?Thin
It keeps 3.6% of sales as profit, up from 0.6% in the year to Dec 2023.
What does it keep on each sale?Rich
It keeps 72¢ of each sales dollar after making what it sells, and spends 46¢ of it on research, its biggest running cost.
Does it earn good returns?Low
Shareholders' money earned 5.1% a year, down from 41% in the year to Dec 2021.
Is it making cash?Strong
It turned 22% of sales into free cash, $14.7B over the last twelve months.
Is the balance sheet safe?Heavy debt
It owes $44.1B more than the cash it holds, about 2.4 years of the cash its operations bring in.
Are shares being diluted?Stable
The share count fell 2.4% in 4.8 years, and pay in shares costs 1.6% of sales.
Why it wins
The evidence
What keeps rivals out is the law, not a secret. American law barred any copy of Keytruda for 12 years after the FDA first approved it, and that bar ended in September 2026. Now only Merck's patents remain, and the main one ends in 2028.
Merck's plan is to move patients to Keytruda Qlex, the same medicine injected under the skin in a few minutes, which carries its own patent to 2043.
Who could beat it
The rivals in full
Three kinds of attack are lined up. Amgen and others are testing cheaper copies of Keytruda for 2028. Summit is testing a new antibody directly against Keytruda in lung cancer. And Halozyme, which owns patents on a similar under-the-skin ingredient, has already had Qlex barred in nine European countries, and is suing in America.
Each rival
Bristol-Myers Squibb (Opdivo and Opdivo Qvantig)BMY
The oncologist writes a rival PD-1 antibody for the same patient; Bristol also sells an under-the-skin version and loses US protection the same year.
Amgen (ABP 234, a proposed Keytruda biosimilar)AMGN
Everything about the infusion: a copy of the same antibody at a lower price once the patents end.
Alvotech with Dr. Reddy's (AVT33)ALVORDY
The same as any biosimilar: the infusion, copied and priced below Merck's.
Cipla with Qilu (a Keytruda biosimilar with US rights)CIPLA.NS
A third copy, from a lower-cost manufacturer, aimed at the US market.
Summit Therapeutics and Akeso (ivonescimab)SMMT9926.HK
Not a copy but a successor: one antibody blocking PD-1 and a tumour's blood supply, tested head-to-head to take Keytruda's place in first-line lung cancer.
Halozyme Therapeutics (patents, not a product)HALO
Not the medicine but the defence: a court order can stop Qlex, leaving patients on the infusion whose patent ends first.
How big it could get
The market and who has signed
The market
About 2.1 million Americans will be told they have cancer in 2026, and researchers estimated that by 2018 nearly half of US cancer patients were eligible for a drug like Keytruda, up from almost none in 2011.
Keytruda's American sales come to about $8,900 for every new case. Nobody has measured eligibility since 2018, and the rest of the world, with 20 million new cases a year, pays far less.
Who runs it
Leaders, pay and the cash
Who runs it
Robert Davis, who came to Merck as finance chief in 2014, has run it since 2021. In 2025 sales fell short of the board's own target, and over three years the shares returned far less than rival drug makers', so that half of the share award paid nothing. The bonus rides on sales, profit and research goals; nothing pays on cash or returns on capital. Insiders each own under 1%.
What they did with the money
Merck is buying its next medicines: Cidara and Terns cost about $16B in 2026, paid in cash and new debt rather than new shares. The share count keeps falling, so each share keeps its slice; the cost shows up as debt and as charges against profit.
The last report
The latest report
Merck's sales rose 5% to $18.1B and Keytruda's injected version reached $830M
What it did to the thesis Solid quarter
It met all three tests we set and put the injected version well ahead of our line. It did not touch what holds us at Neutral: the price already pays for success, and the court cases over the injected version are unresolved.
The report
In the third quarter of 2026 sales rose 5% to $18.1B. Keytruda grew 6% to $8.6B, and its under-the-skin version sold $830M, up from $463M a quarter earlier. Winrevair, the lung-blood-pressure drug, sold $694M, almost double a year ago. About $550M of the growth was customer buying-timing.
Profit per share before some items was $2.49, down 3%, after a $0.12 charge for a licence. Merck narrowed and raised its sales forecast to $66.8B to $67.3B. The FDA also accepted its sac-TMT cancer drug for priority review.
What's happening now
The background
The shares have already moved: up 73.5% in a year, from the cheapest price for each dollar of sales in six years, after trial wins and a pricing deal with the government.
The tests come close together. Third-quarter results arrive on 29 October, a German court hears Merck's appeal over the under-the-skin version on 19 November, and Summit's head-to-head lung-cancer result is due by the end of 2026. Medicare is expected to pick Keytruda for price-setting early in 2027.
Where we disagree
Both sides in full
The market
Merck gets past Keytruda's patent with only a shallow dip, carried by more than 20 new medicines.
We believe
That is possible but not yet earned: the under-the-skin version is in court, and most replacements are not yet on sale.
The argument
The market reads the trial wins as the replacement arriving. We read the dates from the regulator and the law, and the threats from rivals' own filings: copies are in trials and a patent holder has already stopped Qlex in part of Europe.
Against us: three late-stage wins this year, a cholesterol pill approved, and Qlex use rising in America since April. If those keep coming, the market is right.
What it's worth
How we value it
Valued on the analysts' revenue path for three years, each later year closing 30% of the gap to 4%, on official operating profit with stock pay a cost and tax paid in full; the thesis's own evidence is the check on that path.
What the price assumes
Sales growth in the first year, then slowing as ours does, at the same profit per sale.
The price assumed
10.6%
Our estimate
2%
Measured at the close of
6 Nov 2026
The three cases
Bear case$65.17
Growth runs at half the analysts' path, 1%, 3% and 1%, the margin settles a fifth lower at 30.4%, and new capital earns only the 8% rate: the downturn test.
Our value$115
Revenue grows 2%, 5% and 2% over three years, the analysts' path (C63), then fades toward 4%, closing 30% of the gap each year; the margin moves to 38.0%, the analysts' year-three figure after stock pay and on the filed basis (6.5% less).
Bull case$143
Growth runs a quarter above the analysts' path, 3%, 7% and 3%, the margin reaches 41.8%, and new capital earns 15%.
The bet
Seen as a bet
The bet is on Merck's next wave: a cholesterol pill and an HIV pill just approved, and cancer and bowel-disease drugs that succeeded in late trials but are not yet on sale. The rest of Merck is counted separately, at the price buyers pay Bristol for a drug losing its patent at the same time.
If the new medicines succeed, the shares are worth about what they cost today, because the price already pays for them. If they fail, shareholders keep about four-fifths.
What could go wrong
Every risk
The risks
One drug, two deadlines
Half of sales loses its patent in 2028 and gets a government price in 2029, and Merck itself expects American Keytruda sales to fall sharply.
The defence could be blocked
If an American court sides with Halozyme, patients cannot move to the under-the-skin version and the whole franchise meets copies at once.
A better drug
If ivonescimab beats Keytruda in lung cancer, the largest use, doctors may switch before the patent even ends.
Buying growth
Merck pays for new medicines by buying companies and charging the cost to profit; if it keeps doing that, shareholders keep much less than the headline profit.
Trials can fail
One filing was already withdrawn in September 2026 after the FDA said the evidence was not enough.
What we still do not know
How fast American Keytruda sales fall once copies launch and Medicare sets the price, since both arrive within weeks of each other.
What share of Keytruda patients will be on the under-the-skin version by the end of 2028.
Whether ivonescimab beats Keytruda outside China, where it has so far been tested head-to-head.
What changes our view
Every route to a new view
Every route to a new view
→ Neutral
The share price falls to about $138, back within 20% of what we think the business is worth.
→ Attractive
The share price falls to about $91.83, 80% of what we think the business is worth.
→ Attractive
The US patent office's review board finishes striking down the Halozyme patents used against the under-the-skin version. Merck files its three late-stage successes, sac-TMT, intismeran and tulisokibart, in America by the end of 2027.
The next test
It supports the case if
Keytruda family growth of 3% or more, Qlex sales above $830M, and 2027 sales guidance at or above 2026's.
It pressures the case if
Keytruda family growth below 3%, Qlex sales below $830M, or 2027 sales guided below 2026.
We would also be wrong if
A copy of Keytruda is cleared to launch in America before December 2028.
Filings for sac-TMT, intismeran or tulisokibart slip past 2027 or are refused.
The verdict
Scores and how we weighed it
The scores
Growth
2 of 4
Business quality
3 of 4
Financial position
3 of 4
Execution record
3 of 4
Per share capture
4 of 4
Potential
2 of 4
Risk profile
2 of 4
Valuation
1 of 4
Evidence quality
3 of 4
How we weighed it
ValueNegative
The price sits above our value and about at the bull case.
BusinessMixed
A mixed business: a very profitable drug, but half of sales rests on it.
GrowthNegative
Sales barely grew for years, and the main drug faces its patent end and a government price.
RisksNegative
The injected version may be blocked in court, a rival drug may beat Keytruda and half of sales faces a deadline.
RivalsMixed
In the middle of its rivals on sales, above the one facing the same patent date.
The groupMixed
It sits in none of our ranked groups; drug pricing and trial news move it.
Latest newsMixed
The last report met all three tests we set, but a second late-stage drug has since been dropped, a blood-cancer pill stopped on safety grounds.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.